63 related articles for article (PubMed ID: 34997351)
1. [The efficacy of chemotherapy re-challenge in third-line setting for metastatic colorectal cancer patients: a real-world study].
Duan JJ; Ning T; Bai M; Zhang L; Li HL; Liu R; Ge SH; Wang X; Yang YC; Ji Z; Wang FX; Sun YS; Ba Y; Deng T
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):967-972. PubMed ID: 37968083
[No Abstract] [Full Text] [Related]
2. Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study.
Goktas Aydin S; Kavak EE; Topcu A; Bayramgil A; Akgul F; Kahraman S; Aykan MB; Altıntas YE; Helvaci K; Urun Y; Bilici A; Seker M; Sendur MAN; Olmez OF; Acikgoz O; Cicin I
Biomol Biomed; 2023 Nov; 23(6):1089-1095. PubMed ID: 37289436
[TBL] [Abstract][Full Text] [Related]
3. Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405.
Lipsyc-Sharf M; Zhang S; Ou FS; Ma C; McCleary NJ; Niedzwiecki D; Chang IW; Lenz HJ; Blanke CD; Piawah S; Van Loon K; Bainter TM; Venook AP; Mayer RJ; Fuchs CS; Innocenti F; Nixon AB; Goldberg R; O'Reilly EM; Meyerhardt JA; Ng K
J Natl Cancer Inst; 2022 Mar; 114(3):427-435. PubMed ID: 34636852
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Apatinib Plus Programmed Cell Death Protein 1 Blockades for Patients with Treatment-refractory Metastatic Colorectal Cancer: A Retrospective Exploratory Study.
Li S; Zheng H; Ge Q; Xia S; Zhang K; Wang C; Wang F
J Cancer Prev; 2023 Sep; 28(3):106-114. PubMed ID: 37830117
[TBL] [Abstract][Full Text] [Related]
5. Apatinib beyond first progression is associated with prolonged overall survival in patients with advanced breast cancer: Results from an observational study.
Wang J; Jia J; Liu J; Yao X; Yuan Z
Exp Ther Med; 2024 May; 27(5):200. PubMed ID: 38590562
[TBL] [Abstract][Full Text] [Related]
6. Real-Life Effectivity of Dose Intensity Reduction of First-Line mFOLFIRI-Based Treatment of Metastatic Colorectal Cancers: Sometimes Less Is More.
Pécsi B; Mangel L
Curr Oncol; 2023 Jan; 30(1):908-922. PubMed ID: 36661718
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of tyrosine kinase inhibitors for advanced metastatic thyroid cancer: A systematic review and network meta-analysis of randomized controlled trials.
Zhao M; Li R; Song Z; Miao C; Lu J
Medicine (Baltimore); 2024 Apr; 103(15):e37655. PubMed ID: 38608050
[TBL] [Abstract][Full Text] [Related]
8. Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor.
Jang S; Strickland B; Finis L; Kooijman JJ; Melis JJTM; Zaman GJR; Van Tornout J
Cancer Chemother Pharmacol; 2023 Jun; 91(6):491-499. PubMed ID: 37148323
[TBL] [Abstract][Full Text] [Related]
9. ARL9 is upregulated and serves as a biomarker for a poor prognosis in colon adenocarcinoma.
Yang HD; Jin XX; Gu BB; Yu-Zhang ; Li D; Yan LL
BMC Gastroenterol; 2023 Feb; 23(1):48. PubMed ID: 36823542
[TBL] [Abstract][Full Text] [Related]
10. Apatinib: A Novel Antiangiogenic Drug in Monotherapy or Combination Immunotherapy for Digestive System Malignancies.
Li H; Huang H; Zhang T; Feng H; Wang S; Zhang Y; Ji X; Cheng X; Zhao R
Front Immunol; 2022; 13():937307. PubMed ID: 35844616
[TBL] [Abstract][Full Text] [Related]
11. Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients.
Pan D; Liu D; Liang L; Shen T; Shi C; Qin H
Front Oncol; 2022; 12():863392. PubMed ID: 35664730
[TBL] [Abstract][Full Text] [Related]
12. Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer: An analysis of the prospective QoLiTrap study.
Piringer G; Thaler J; Anchisi S; Geffriaud-Ricouard C; Gueldner M; Scholten F; Derigs HG; Bohanes P; Grünberger B; Schwarz L; von Moos R; Hofheinz RD
J Geriatr Oncol; 2023 Nov; 14(8):101638. PubMed ID: 37776611
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen.
Martínez-Lago N; Cameselle García S; Alonso de Castro B; Gómez-Randulfe Rodríguez MI; Carmona Campos M; González Villarroel P; Salgado Fernández M; De la Cámara Gómez JC; Romero Reinoso C; Cousillas Castiñeiras A; Méndez Méndez JC; Vidal Insua Y; Fernández-Montes A
PLoS One; 2022; 17(6):e0269399. PubMed ID: 35657983
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
15. A systemic review and meta-analysis of Aflibercept plus FOLFIRI regimen as a second-line treatment for metastatic colorectal cancer: A PRISMA compliant pooled analysis of randomized controlled trials and single arm studies to assess efficacy and safety.
Thakur A; Chorawala MR; Patel RS
Crit Rev Oncol Hematol; 2023 Aug; 188():104034. PubMed ID: 37257732
[TBL] [Abstract][Full Text] [Related]
16. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence.
Wade R; Duarte A; Simmonds M; Rodriguez-Lopez R; Duffy S; Woolacott N; Spackman E
Pharmacoeconomics; 2015 May; 33(5):457-66. PubMed ID: 25616671
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer.
Rong X; Liu H; Yu H; Zhao J; Wang J; Wang Y
Invest New Drugs; 2022 Apr; 40(2):340-348. PubMed ID: 34997351
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
